[go: up one dir, main page]

PE32296A1 - Ester de l-monovalina derivado de 2-(2-amino-1,6-dihidro-6-oxo-purin-9-il) metoxi-1,3-propandiol y sus sales farmaceuticamente aceptables - Google Patents

Ester de l-monovalina derivado de 2-(2-amino-1,6-dihidro-6-oxo-purin-9-il) metoxi-1,3-propandiol y sus sales farmaceuticamente aceptables

Info

Publication number
PE32296A1
PE32296A1 PE1995273436A PE27343695A PE32296A1 PE 32296 A1 PE32296 A1 PE 32296A1 PE 1995273436 A PE1995273436 A PE 1995273436A PE 27343695 A PE27343695 A PE 27343695A PE 32296 A1 PE32296 A1 PE 32296A1
Authority
PE
Peru
Prior art keywords
metoxi
purin
oxo
amino
pharmaceutically acceptable
Prior art date
Application number
PE1995273436A
Other languages
English (en)
Inventor
Scott W Womble
John J Nestor
Hans Maag
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23079211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE32296(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE32296A1 publication Critical patent/PE32296A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE REFIERE AL COMPUESTO 2-(2-AMINO-1,6-DIHIDRO-6-OXO-PURIN-9-IL)METOXI-3-HIDROXI-1-PROPANIL-L-VALINATO o MONO-L-VALINA GANCICLOVIR O UNA SAL RESPECTIVA TAL COMO CLORHIDRATO O ACETATO EN FORMA DE SUS DIASTEREOMEROS R(-) o S(-), O EN FORMA DE MEZCLAS DE LOS DOS DIASTEREOMEROS EN IGUALES PROPORCIONES, EN DONDE EL (R)- ES 2-(2-AMINO-1,6-DIHIDRO-6-OXO-PURIN-9-IL )METOXI-3-HIDROXI-1-PROPANIL-L-VALINATO Y EL (S)- ES 2-(2-AMINO-1,6-DIHIDRO-6-OXO-PURIN-9-IL)METOXI-3-HIDROXI-1-PROPANIL-L-VALINATO. ESTOS COMPUESTOS OPCIONALMENTE TIENE UN EXCIPIENTE O VEHICULO FARMACEUTICAMENTE ACEPTABLE PARA ADMINISTRACION ORAL, TOPICA O COMO IMPLANTE INTRAVITREAL Y SON UTILIZADOS EN EL TRATAMIENTO DE INFECCIONES HERPETICAS EN PACIENTES INMUNOCOMPROMETIDOS
PE1995273436A 1994-07-28 1995-07-10 Ester de l-monovalina derivado de 2-(2-amino-1,6-dihidro-6-oxo-purin-9-il) metoxi-1,3-propandiol y sus sales farmaceuticamente aceptables PE32296A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28189394A 1994-07-28 1994-07-28

Publications (1)

Publication Number Publication Date
PE32296A1 true PE32296A1 (es) 1996-08-07

Family

ID=23079211

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1995273436A PE32296A1 (es) 1994-07-28 1995-07-10 Ester de l-monovalina derivado de 2-(2-amino-1,6-dihidro-6-oxo-purin-9-il) metoxi-1,3-propandiol y sus sales farmaceuticamente aceptables

Country Status (32)

Country Link
EP (1) EP0694547B1 (es)
JP (1) JP3090305B2 (es)
KR (1) KR100358626B1 (es)
CN (1) CN1045089C (es)
AT (1) ATE179173T1 (es)
AU (1) AU697107B2 (es)
BR (1) BR9503468A (es)
CA (1) CA2154721C (es)
CO (1) CO4410181A1 (es)
CY (2) CY2180B1 (es)
CZ (1) CZ290511B6 (es)
DE (3) DE69509173T2 (es)
DK (1) DK0694547T3 (es)
ES (1) ES2083348T3 (es)
FI (1) FI112080B (es)
GR (2) GR960300021T1 (es)
HU (1) HU216867B (es)
IL (1) IL114735A (es)
LU (1) LU91136I2 (es)
MA (1) MA23631A1 (es)
MY (1) MY114393A (es)
NL (1) NL300071I2 (es)
NO (2) NO312899B1 (es)
NZ (1) NZ272652A (es)
PE (1) PE32296A1 (es)
PL (1) PL180609B1 (es)
RU (1) RU2133749C1 (es)
SA (1) SA95160158B1 (es)
TR (1) TR199500895A2 (es)
TW (1) TW434242B (es)
UY (1) UY24006A1 (es)
ZA (1) ZA956228B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458772B1 (en) 1909-10-07 2002-10-01 Medivir Ab Prodrugs
AU1592897A (en) * 1996-01-26 1997-08-20 F. Hoffmann-La Roche Ag Process for preparing purine derivatives
US5756736A (en) * 1996-01-26 1998-05-26 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
ES2180923T5 (es) * 1996-01-26 2005-10-16 F. Hoffmann-La Roche Ag Proceso para la preparacion de derivados de purina.
US5840890A (en) * 1996-01-26 1998-11-24 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
US5700936A (en) * 1996-01-26 1997-12-23 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol valinate
US6703394B2 (en) 1996-02-16 2004-03-09 Medivir Ab Acyclic nucleoside derivatives
US5869493A (en) * 1996-02-16 1999-02-09 Medivir Ab Acyclic nucleoside derivatives
WO1998034917A2 (en) * 1997-02-10 1998-08-13 Medivir Ab Synthesis of acyclic nucleoside derivatives
US6184376B1 (en) 1997-02-10 2001-02-06 Mediver Ab Synthesis of acyclic nucleoside derivatives
PT988304E (pt) * 1997-08-15 2001-10-31 Medivir Ab Analogos de nucleosidos tais como os antivirais que contem inibidores de transcritase reversa retroviral e de adn-polimerase do virus da hepatite b (hbv)
WO1999032490A1 (en) * 1997-12-19 1999-07-01 Bristol-Myers Squibb Company Prodrugs of lobucavir and methods of use
WO1999051613A1 (en) * 1998-04-03 1999-10-14 Medivir Ab Prodrugs of phosphorous-containing pharmaceuticals
JP2000256359A (ja) * 1999-03-11 2000-09-19 Japan Science & Technology Corp 面性キラリティーを有する分子群の高選択的不斉変換法
KR20030015655A (ko) * 2001-08-17 2003-02-25 한미약품공업 주식회사 항암제의 경구흡수율을 증가시키는 인단계 화합물의결정성 산부가염, 이의 제조방법 및 이를 함유하는 약학적조성물
ATE361910T1 (de) * 2002-04-23 2007-06-15 Aventis Pharma Inc 3-(pyridinyl-amino)-1h-indol-2-carbonsäure- verbindungen als inhibitoren der interleukin-4 genexpression
AU2003273000A1 (en) 2002-10-16 2004-05-04 Takeda Pharmaceutical Company Limited Stable solid preparations
EA201100293A1 (ru) 2003-01-14 2011-08-30 Джилид Сайэнс, Инк. Способ (варианты) и фармацевтическая композиция (варианты) для лечения или профилактики симптомов вич-инфекции
WO2005021549A1 (en) * 2003-08-28 2005-03-10 Ranbaxy Laboratories Limited Amorphous valganciclovir hydrochloride
WO2006009602A2 (en) 2004-06-16 2006-01-26 Tap Pharmaceutical Products, Inc. Multiple ppi dosage form
US7872095B2 (en) * 2004-07-19 2011-01-18 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
ZA200702234B (en) * 2006-03-21 2008-07-30 Cipla Ltd Preparation of ester of purine derivatives
KR20100116165A (ko) 2007-10-12 2010-10-29 다케다 파마슈티칼스 노쓰 어메리카, 인코포레이티드 음식 섭취와 관계없이 위장 장애를 치료하는 방법
EP2714691B1 (en) * 2011-05-31 2016-09-07 Pharmathen S.A. Process for the preparation of 2-amino-9-((2-phenyl-1,3-dioxan-5-yloxy)methyl)-1h-purin-6(9h)-one compound useful in the preparation of valganciclovir
KR102312533B1 (ko) 2021-02-24 2021-10-15 주식회사 이웅 자동 스패너

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8202626A (nl) * 1982-06-29 1984-01-16 Stichting Rega V Z W Derivaten van 9-(2-hydroxyethoxymethyl)guanine.
US4897479A (en) * 1983-09-30 1990-01-30 Merck & Co., Inc. Arylsulfonyloxy purine intermediates
IE842642L (en) * 1983-10-31 1985-04-30 Harvard College Purine Derivatives
DK168213B1 (da) * 1984-12-12 1994-02-28 Syntex Inc Alkoxymethylether- og alkoxymethylesterderivater af glycerol og fremgangsmåde til fremstilling af 9-(1,3-dihydroxy-2-propoxymethyl)guanin og ethere og estere deraf
AP160A (en) * 1987-08-15 1991-11-18 The Wellcome Foundation Ltd Therapeutic acyclic nucleosides.
EP0375329B1 (en) * 1988-12-19 1995-05-31 The Wellcome Foundation Limited Antiviral pyrimidine and purine compounds, process for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
FI953592L (fi) 1996-01-29
MA23631A1 (fr) 1996-04-01
EP0694547A3 (en) 1996-06-05
CA2154721A1 (en) 1996-01-29
NL300071I1 (nl) 2002-02-01
HU9502238D0 (en) 1995-09-28
NZ272652A (en) 1996-12-20
CY2004003I1 (el) 2009-11-04
DE10299032I1 (de) 2003-01-23
CZ193995A3 (en) 1996-02-14
PL180609B1 (pl) 2001-03-30
TR199500895A2 (tr) 1996-06-21
CN1045089C (zh) 1999-09-15
EP0694547B1 (en) 1999-04-21
MY114393A (en) 2002-10-31
GR960300021T1 (en) 1996-04-30
EP0694547A2 (en) 1996-01-31
GR3030678T3 (en) 1999-11-30
HUT73246A (en) 1996-07-29
PL309812A1 (en) 1996-02-05
RU95113148A (ru) 1997-06-27
IL114735A (en) 1998-06-15
SA95160158B1 (ar) 2006-05-20
BR9503468A (pt) 1996-02-27
DE69509173T2 (de) 1999-10-21
CY2004003I2 (el) 2009-11-04
FI953592A0 (fi) 1995-07-27
IL114735A0 (en) 1995-11-27
DE10299032I2 (de) 2006-06-14
ZA956228B (en) 1996-02-22
ATE179173T1 (de) 1999-05-15
CY2180B1 (en) 2002-08-23
AU697107B2 (en) 1998-09-24
NL300071I2 (nl) 2002-03-01
FI112080B (fi) 2003-10-31
NO2003001I2 (no) 2007-06-11
TW434242B (en) 2001-05-16
UY24006A1 (es) 2001-07-31
DE694547T1 (de) 1996-10-24
DE69509173D1 (de) 1999-05-27
CA2154721C (en) 2001-01-02
NO952977L (no) 1996-01-29
CO4410181A1 (es) 1997-01-09
CN1122804A (zh) 1996-05-22
NO952977D0 (no) 1995-07-27
KR960004345A (ko) 1996-02-23
JPH0841061A (ja) 1996-02-13
ES2083348T1 (es) 1996-04-16
NO312899B1 (no) 2002-07-15
CZ290511B6 (cs) 2002-08-14
ES2083348T3 (es) 1999-08-01
LU91136I2 (fr) 2005-07-06
RU2133749C1 (ru) 1999-07-27
AU2719595A (en) 1996-02-08
DK0694547T3 (da) 2000-01-03
HK1012339A1 (en) 1999-07-30
JP3090305B2 (ja) 2000-09-18
KR100358626B1 (ko) 2003-01-14
HU216867B (hu) 1999-09-28

Similar Documents

Publication Publication Date Title
PE32296A1 (es) Ester de l-monovalina derivado de 2-(2-amino-1,6-dihidro-6-oxo-purin-9-il) metoxi-1,3-propandiol y sus sales farmaceuticamente aceptables
AR009069A1 (es) Arilalcanoilpiridazinas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen, y un procedimiento para obtener estas preparaciones farmaceuticas
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
HUP0203575A2 (hu) Th2 differenciálódás inhibitorokat tartalmazó gyógyszerkészítmények és alkalmazásuk
BG100016A (bg) Нiv протеазни инхибитори във фармацевтични комбинации за лечение на спин
ES2150577T3 (es) Aminoeteres aromaticos como agentes para aliviar el dolor.
EA199800184A1 (ru) Соединение бензимидазола
AR002751A1 (es) Antifungicos de tetrahidrofurano, composiciones farmaceuticas que los contienen y el uso de los compuestos para preparar composiciones farmaceuticas utiles para el tratamiento de infecciones fungicas
AR070473A2 (es) Compuestos inhibidores de la renina, un procedimiento de preparacion del compuesto, una composicion farmaceutica, uso del compuesto para preparar un medicamento y compuesto intermediario
AR029766A1 (es) Compuesto inhibidor de quinasa y uso del mismo para preparar una composicion farmaceutica
MX9303441A (es) Procedimiento para la preparacion de acido clavulanico.
CO4940486A1 (es) Composiciones anti-fungosas
PA8432901A1 (es) Compuestos de piridilpirrol
RU94044436A (ru) Способы подавления атрофии кожи и влагалища
RU93005057A (ru) Фармацевтические соединения, производные тиенобензодиазепина, способ их получения, фармкомпозиция и их использование
HUP0001269A2 (hu) 2-Oxo-1-azetidin-szulfonsav-származékok és ezeket tartalmazó kombinált gyógyszerkészítmények
AU3850600A (en) Dalda analogs and their use
ES2141957T3 (es) Uso de raloxifeno y sus analogos para la produccion de un medicamento para el tratamiento de enfermedades virales.
NO307687B1 (no) Anvendelse av riluzol ved fremstilling av medikamenter for behandling av neuro-AIDS
RU2002100058A (ru) Кристаллические производные 1-метилкарбапенема
ES2180933T3 (es) Inhibidor de la serina-proteasa.
AR050463A1 (es) Analagos de lonidamina y su uso en anticoncepcion masculina y en el tratamiento contra el cancer.
RU2017133660A (ru) Новые гетероциклические соединения и их применение в профилактике или лечении бактериальных инфекций
AR007021A1 (es) Derivados de 3-descladinosa-2,3-anhidroeritromicina, procedimientos para su preparacion, compuestos para su exclusivo uso en dichos procedimientosy procedimiento para su preparacion, una composicion farmaceutica para tratar infecciones bacterianas y el uso de estos compuestos para preparar medicamentos
AR040274A1 (es) Derivados de 1-[(indol-3-il)carbonil]piperazina como agonistas de canabinoides en el tratamiento del dolor y composiciones farmaceuticas

Legal Events

Date Code Title Description
FG Grant, registration
MK Expiration of term